Dr. Justin Kline, MD
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Studies Lymphoma
Studies Diffuse Large B-Cell Lymphoma
8 reported clinical trials
9 drugs studied
Area of expertise
1Lymphoma
PD-L1 positive
MYC positive
BCL2 positive
2Diffuse Large B-Cell Lymphoma
PD-L1 positive
MYC positive
BCL2 positive
Affiliated Hospitals
Clinical Trials Justin Kline, MD is currently running
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Nivolumab is an antibody that enhances the immune system to better fight Hodgkin lymphoma cells. Giving brentuximab vedotin and nivolumab may be able to defer stem cell transplant treatment and spare the considerable cost and toxicity on transplantation.
Recruiting1 award Phase 224 criteria
Post-CAR T-cell Therapy Drug Combo
for Non-Hodgkin's Lymphoma
This trial is testing two treatments, mosunetuzumab and polatuzumab vedotin, for patients with certain types of lymphoma that have come back or don't respond to other treatments. These treatments aim to stop cancer cells from growing or kill them directly. The goal is to see if these treatments can better control or shrink the cancer compared to not using them.
Recruiting1 award Phase 2
More about Justin Kline, MD
Clinical Trial Related6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Justin Kline, MD has experience with
- Nivolumab
- Pembrolizumab
- R-CHOP Protocol
- Brentuximab Vedotin
- Ipilimumab
- Varlilumab
Breakdown of trials Justin Kline, MD has run
Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Mediastinal Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Justin Kline, MD specialize in?
Justin Kline, MD focuses on Lymphoma and Diffuse Large B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved PD-L1 positive patients, or patients who are MYC positive.
Is Justin Kline, MD currently recruiting for clinical trials?
Yes, Justin Kline, MD is currently recruiting for 3 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Justin Kline, MD has studied deeply?
Yes, Justin Kline, MD has studied treatments such as Nivolumab, Pembrolizumab, R-CHOP Protocol.
What is the best way to schedule an appointment with Justin Kline, MD?
Apply for one of the trials that Justin Kline, MD is conducting.
What is the office address of Justin Kline, MD?
The office of Justin Kline, MD is located at: University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.